Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. - sprookjes - yvandenbroek - TriplyDB

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

http://www.wikidata.org/entity/Q33756662

about

Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy Immunotherapy for prostate cancer: recent developments and future challenges From bench to bedside: immunotherapy for prostate cancer Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation Immunosuppressive strategies that are mediated by tumor cells Age-dependent tolerance to an endogenous tumor-associated antigen.iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells.Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications Preclinical and clinical development of DNA vaccines for prostate cancer.Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis.Self-antigen prevents CD8 T cell effector differentiation by CD134 and CD137 dual costimulation.Histone acetylation at the Ifng promoter in tolerized CD4 cells is associated with increased IFN-gamma expression during subsequent immunization to the same antigen Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses.The E3 ubiquitin ligase Cbl-b regulates expansion but not functional activity of self-reactive CD4 T cells In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice.Shaping the repertoire of tumor-infiltrating effector and regulatory T cells.Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.Exploiting synergy: immune-based combinations in the treatment of prostate cancer.LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression.Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells.Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells Prostate cancer as a model for tumour immunotherapy.Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.New insights into androgenic immune regulation Proposed mechanisms of action for prostate cancer vaccines.Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model Prostate cancer immunotherapy.Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer Combining Vaccines with Conventional Therapies for Cancer.Enhancing efficacy of therapeutic vaccinations by combination with other modalities.Update on prostate cancer vaccines The current and emerging role of immunotherapy in prostate cancer Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4(+) T cell receptor repertoire clonality Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.

P2860

Q26740601-6FF5A96A-4B1B-4C6A-9AC4-A5C93FCA987C Q26749571-EEB8B690-EA7D-439C-99E9-92ECB836BDAF Q26827475-A2B3CFBC-93FB-40AD-8398-F8D84B8C7395 Q26851608-FA8843A0-7E11-40B4-A3B2-9212FCB22F61 Q26852388-337F75E0-EB16-4766-90D8-57D8B336461D Q26864390-A610D9F0-2BB7-4AD7-9617-83673C31631B Q28655545-271F1FEA-7538-4DA2-A9C6-52B92982A7F4 Q29636247-71260A69-EAFE-4B67-8A4A-1D7698448F06 Q30439993-3DF64255-C725-4743-A53A-781ACD308098 Q33523809-3593B948-9CB2-47AF-B17D-8689F8CBA0A9 Q33621393-1AEEF0E5-E386-4315-A578-61BC6B5D4CAB Q33740811-BBA80D48-B705-4A6A-999F-31161755D4D1 Q33756652-1A30841D-180E-4596-8C56-6D45BFB82BB3 Q33756678-54A45E60-D63E-422E-8C37-8EB7E6089687 Q33791226-8B284ADF-D8D6-45EE-876D-E312688A4043 Q33798326-54D181F7-F210-4D70-A03F-EA1ED0F57B91 Q33802637-0B2F34C0-503C-4E00-9520-EB8AE986A229 Q33837085-474AB880-0DE1-4FC9-8BA5-2578406BC515 Q33872776-CF82BB2E-2352-49C9-B26D-DC007764FBB0 Q34003592-72E69DE4-D638-467D-9E50-E5AA6850CE10 Q34321844-02574FF0-5BFF-4F72-A483-340F5C3EE060 Q34687216-0CDC2A5F-C2C9-4C52-940F-8B18118C0579 Q34700552-46EF694F-D367-45F7-A738-75CA16C65225 Q34755544-AEF8F8DE-51EC-43AE-90A7-5EC6767C6C29 Q34856691-1A422C42-CAA5-4E67-A010-502A60452391 Q34856800-64010491-451C-4A9D-9E84-F6F022DF3B99 Q34856875-D36E9735-4E72-4466-9D05-4CBD9360A6CF Q34887495-2ED86FCF-6EDD-49FD-A843-7AF386C361FD Q34936575-D0439D48-BCE5-4168-9ABB-C1AF49B257E6 Q35174754-3EC2ACDD-9A35-45A4-AE59-9B7A7246B6F9 Q35641792-1C9945E1-31BD-48B7-A623-7361E92B4DBA Q35688425-6DFE68A9-D93A-439D-BBC4-DC31A644D8EB Q35951653-7E9FC2AF-4DE7-46A5-85DF-AFB6F15441ED Q36082331-AE7F3519-6953-4934-9FE8-902AD62C7F42 Q36113943-42B49065-6B26-4F28-BFF0-A675C85D8108 Q36169608-A40ECC90-CB89-499F-AB34-DCD9C2899E7F Q36249922-984E8BB3-AA5B-4777-B15C-F1F31B256CF6 Q36254081-DDE2DCC2-D495-4CC6-A769-00F8B21C9B32 Q36256308-3E3E2611-C21F-47F0-BECA-9513273BB3FF Q36285594-D85B0186-5E02-48FB-B69E-C587B1ADD98D

P2860

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

http://www.wikidata.org/entity/Q33756662

description

2005 nî lūn-bûn

@nan

2005 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մարտին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

@ast

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

@en

type

label

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

@ast

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

@en

prefLabel

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

@ast

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

@en

P1433

Q33756662-A4E8E85C-C9B7-4A6F-A1D5-88D0610893D1

P1476

Q33756662-C91A9840-F6BA-4464-B7EC-585E78B71AF9

P2093

Q33756662-40A5177F-6B2C-472F-A9FB-E7E5566BD106

Q33756662-46347524-3AEE-4B17-9463-6B23FD6142E9

Q33756662-4BCF9779-F7A1-407A-A298-7F5A0FE10271

Q33756662-5CC766B6-8978-4CC5-B12E-B1E251D19E39

Q33756662-8CFEE01C-5B3F-4C8C-8082-BF85A1373812

Q33756662-9197B43A-27F0-4316-8D9C-0F9908BA7BAF

Q33756662-91F0EBB6-60E9-4A4D-A587-9220C3A5F203

Q33756662-9CA037E5-47A7-48EE-A01D-6E5A96DE1289

Q33756662-A5DB8169-BE38-43FF-B39A-2484AD6E4E22

Q33756662-AE28A87D-1945-4277-92C4-57365BAB94D9

P2860

Q33756662-107B5ECB-74FD-4E99-9459-D408C0D89A4E

Q33756662-1285AD9A-8323-441B-BD68-3DA271FD57B1

Q33756662-1A9A8F38-6E1E-484B-A38E-E7666DE398E2

Q33756662-1BF724EF-1893-4DC3-8B60-D18ABF1C779F

Q33756662-1F4D13D5-8338-4E93-803B-BC1C7B7F4DEA

Q33756662-2C90FAF5-1CA5-4207-AC8E-D609EFB370FB

Q33756662-30F5BBFE-9411-4562-B463-92A2201B2386

Q33756662-33F7DB62-D579-48FA-873A-18A90FFB8CC2

Q33756662-38C72F97-7BF1-49CA-B3E9-E7C98866D7E9

Q33756662-4A930FD9-9937-4525-AD19-FCC94184DC65

P304

Q33756662-973CE0A0-67AC-4630-A7C3-86E353A6EBB9

P31

Q33756662-9B85BFB1-54D9-42DB-BC0F-220FE5A58D24

P356

Q33756662-B10E4439-4D60-4812-BE22-43A861209277

P433

Q33756662-1A2A6C45-4C13-4218-AF6F-D141F2B933EA

P478

Q33756662-CB047448-2AE1-49A1-B505-B2F8BF602C38

P577

Q33756662-8B327BAC-7FB9-498D-BC81-44C2AD9E29F8

P5875

Q33756662-8BB6057D-DCCB-4C5A-9A10-FD540845AA9F

P698

Q33756662-A0A2E020-776D-4FC7-BBC8-E34EBCA90A61

P932

Q33756662-7D2009C8-5A56-4837-9FA7-ECEA6B2B114A

P356

J.CCR.2005.01.027

P1433

P1476

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

@en

P2093

Adam J Adler

http://www.w3.org/2001/XMLSchema#string

Amy D H Doody

http://www.w3.org/2001/XMLSchema#string

Charles G Drake

http://www.w3.org/2001/XMLSchema#string

Ching-Tai Huang

http://www.w3.org/2001/XMLSchema#string

Dallas B Flies

http://www.w3.org/2001/XMLSchema#string

Drew M Pardoll

http://www.w3.org/2001/XMLSchema#string

Edward L Hipkiss

http://www.w3.org/2001/XMLSchema#string

Erin Kelleher

http://www.w3.org/2001/XMLSchema#string

Eugene P Kennedy

http://www.w3.org/2001/XMLSchema#string

Lee Coryell

http://www.w3.org/2001/XMLSchema#string

P2860

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

The induction of tolerance by dendritic cells that have captured apoptotic cells

Immune tolerance after delivery of dying cells to dendritic cells in situ

Projection of an immunological self shadow within the thymus by the aire protein

Molecular determinants of resistance to antiandrogen therapy

Cytotoxic T cell recognition of the influenza nucleoprotein and hemagglutinin expressed in transfected mouse L cells.

In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy.

Effector CD4 cell tolerization is mediated through functional inactivation and involves preferential impairment of TNF-alpha and IFN-gamma expression potentials.

Effector CD4 cells are tolerized upon exposure to parenchymal self-antigen.

T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer.

P304

239-249

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCR.2005.01.027

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7967306

http://www.w3.org/2001/XMLSchema#string

P698

15766662

http://www.w3.org/2001/XMLSchema#string

P932

2846360

http://www.w3.org/2001/XMLSchema#string